J.ophthalmol.(Ukraine).2019;5:18-21.

http://doi.org/10.31288/oftalmolzh201951821

Received: 15 July 2019; Published: 30 October 2019


Blood sICAM-1 levels in type 2 diabetes mellitus patients with various grades of DME

S.A. Suk1, Cand Sc (Med); M. L. Kyryliuk2, Dr Sc (Med), Prof.; S. O. Rykov1, Dr Sc (Med), Prof.

1 Shupik National Medical Academy of Postgraduate Education, Ministry of Health of Ukraine; Kyiv (Ukraine)

2 Ukrainian Research Center for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues;  Kyiv (Ukraine)

E-mail: sasuk1972@gmail.commlkyryliuk@endosurg.com.ua, eye-bolit@ukr.net

TO CITE THIS ARTICLE: Suk SA, Kyryliuk ML, Rykov SO. Blood sICAM-1 levels in type 2 diabetes mellitus patients with various grades of DME. J.ophthalmol.(Ukraine).2019;5:18-21. http://doi.org/10.31288/oftalmolzh201951821

 

Background: Diabetic macular edema (DME) is a major cause of visual impairment in type 2 diabetes mellitus (DM) patients. Non-specific inflammation is an important factor of the underlying processes of DME. Intercellular adhesion molecules (ICAM), particularly, soluble ICAM-1 (s-ICAM-1), are a local inflammatory mediator involved in the pathogenesis of diabetic injury to the layers of the eye. The literature is scant on the assessment of sICAM-1 blood levels in type 2 DM patients with diabetic injury to the neurovascular system of the eye.

Purpose: To investigate serum sICAM-1 levels in type 2 DM patients with various grades of DME.

Materials and Methods: Eighty-two type 2 DM patients (145 eyes) were involved in the study; they were divided into four groups based on DME severity. Patients underwent laboratory examination (glycated hemoglobin A1c, HbA1c) and comprehensive eye examination. Inclusion criteria were voluntary informed consent, age above 18 years, and presence of type 2 DM. Exclusion criteria were pregnancy, presence of endocrine disorders that may lead to type 2 DM (Cushing's syndrome, acromegalia, dispituitarism, polycystic ovaries syndrome, etc.), coagulation system impairment, neurodegenerative disorders of the central nervous system, type 1 DM, acute infectious disorders, cancer, decompensation of concomitant medical conditions, mental disorders, administration of neuroleptics and/or antidepressants, or presence of proteinuria, glaucoma or mature cataract. Serum sICAM-1 levels were determined by enzyme-linked immunosorbent assay (ELISA). Single-factor analysis of variance was used for statistical analysis.

Results: The median serum sICAM-1 level value for DME0 group (Me = 600.3 ng/mL (593.1 ng/mL – 610.1 ng/mL)) was statistically significantly (p = 0.01) higher than for conventionally amalgamated (DME1 – DME3) group (Me = 558.5 ng/mL (506.9 ng/mL – 607 ng/mL)).

Conclusion:  The median serum sICAM-1 level value for patients with DME0 (Me = 600.3 ng/mL (593.1 ng/mL – 610.1 ng/mL)) was statistically significantly (p = 0.01) higher than for those with DME1 to DME3 (Me = 558.5 ng/mL (506.9 ng/mL – 607 ng/mL)).

Keywords: diabetic macular edema, type 2 diabetes mellitus, sICAM-1

References

1.Pasyechnikiva NV, Suk SA, Kuznetsova TA, Parkhomenko OG. [Diabetic maculopathy. Current aspects of the pathogenesis, clinical picture, diagnosis and treatment]. Kyiv: Karbon LTD;2010. Russian.

2.Yang L, Froio RM, Sciuto TE, et al. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood. 2005 Jul 15;106(2):584-92.

Crossref   PubMed 

3.Abu El-Asrar, AM, Al-Mezaine HS, Ola MS.  Pathophysiology and Management of Diabetic Retinopathy. Expert Rev Ophthalmol. 2009;4(6):627-47.

Crossref   

4.Xie Z, Liang H. Association between diabetic retinopathy in type 2 diabetes and the ICAM-1 rs5498 polymorphism: a meta-analysis of case-control studies.  BMC Ophthalmology. 2018;18:297. 

Crossref   PubMed  

5.American Academy of Ophthalmology Retina -Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2014. Available at: www.aao.org/ppp.

6.Jekel JF, Katz DL, Elmore JG, Wild DMG. Epidemiology, biostatistics, and preventive medicine. 3rd ed. Philadelphia: Saunders Elsevier; 2007.

7.Funatsu H., Yamashita H., Sakata K. et al. Vitreous Levels of Vascular Endothelial Growth Factor and Intercellular Adhesion Molecule 1 Are Related to Diabetic Macular Edema. Ophthalmology. June 2005; 112(5):806-16. DOI: 10.1016/j.ophtha.2004.11.045

8.Zhu D, Zhu H, Wang C, Yang D.  Intraocular soluble intracellular adhesion molecule-1 correlates with subretinal fluid height of diabetic macular edema. Indian J Ophthalmol. 2014 Mar;62(3):295-8. doi: 10.4103/0301-4738.111184.

Crossref    PubMed

9.Hillier RJ, Ojaimi E, Wong DT, et al. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema. JAMA Ophthalmol. 2018 Apr 1;136(4):382-388. 

Crossref   PubMed  

10.Pylypenko LYu, Serdiuk VM. [Effect of diabetic retinopathy progression factors on the content of marker of adhesive endothelial dysfunction VCAM-1 in the blood at type 2 diabetes mellitus as a cluster of metabolic syndrome]. Archive of Ukrainian Ophthalmology. 2018;6(1(10)):42-7. Russian.

11.Serdiuk VM, Kyryliuk ML, Pylypenko LYu. Activity of plasminogen activator inhibitor-1 in blood of patients with metabolic syndrome depending on a stage of diabetic retinopathy. J Ophthalmol (Ukraine). 2018;3:52-56. 

Crossref   

 

All authors declare that they have neither financial nor non-financial competing interests.